Treatment eligibility in hepatitis B: a call for better linkage to optimal care

Lancet Gastroenterol Hepatol. 2021 Mar;6(3):160. doi: 10.1016/S2468-1253(20)30391-5.

Authors

Daniel Q Huang¹, Mindie H Nguyen²

Affiliations

¹ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore.
² Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA, USA; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. Electronic address: mindiehn@stanford.edu.

PMID: 33581753
DOI: 10.1016/S2468-1253(20)30391-5

No abstract available

Publication types

Letter
Comment

MeSH terms

Antiviral Agents / therapeutic use
Hepatitis B Surface Antigens
Hepatitis B* / diagnosis
Hepatitis B* / drug therapy
Hepatitis B* / epidemiology
Hepatitis B, Chronic* / drug therapy
Hepatitis B, Chronic* / epidemiology
Hepatitis B, Chronic* / prevention & control
Humans

Substances

Antiviral Agents
Hepatitis B Surface Antigens